ASCO 2013 - Poster: Pain analyses from the phase III randomized ALSYMPCA study with radium-223 dichloride in castration-resistant prostate cancer (CRPC) patients with bone metastases

CHICAGO, IL USA ( - Presented by S. Nilsson,1 O. Sartor,2 Ø. Bruland,3 F. Fang,4A-K. Aksnes,5 P. Cislo,4 C. Parker6 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco nilsson 5038 Ra223 pain thumb

1Karolinska University Hospital, Stockholm, Sweden; 2Tulane Cancer Center, New Orleans, LA, USA; 3University of Oslo, The Norwegian Radium Hospital, Oslo, Norway; 4Bayer HealthCare, Montville, NJ, USA; 5Algeta ASA, Oslo Norway; 6The Royal Marsden NHS Foundation Trust, Sutton, UK


The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage





Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.